

# Chordate Medical presents interim report for Q1 2023

**Chordate Medical Holding (publ) publishes its interim report for Q1 2023 on Thursday, May 25th, 2023, 08:30 a.m. On Friday, May 26th, 10:00 a.m., the company invites you to a live-streamed teleconference with CEO Anders Weilandt.**

After the conference, there will be a question-and-answer session. The presentation is held in Swedish. It is possible to follow the conference via computer or mobile devices.

Register for the web conference here: <https://attendee.gotowebinar.com/register/6316614468544567648>

The number of places is limited, so we recommend registering well in advance to secure a place.

A recording of the web conference will be available after the conference on the company's website [www.chordate.com](http://www.chordate.com) and on the Västra Hamnen Corporate Finance [YouTube channel](#).

**For more information, please contact:**

Anders Weilandt, CEO  
[anders.weilandt@chordate.com](mailto:anders.weilandt@chordate.com)  
Cell: +46 733-874277

**About Chordate**

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at [www.chordate.com](http://www.chordate.com)

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

*N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.*

**Attachments**

[Chordate Medical presents interim report for Q1 2023](#)